Fadolmidine (development code MPV-2426) is an experimental ñ adrenergic receptor agonist that has been investigated as a spinal analgesic. It was developed with the aim of providing antinociceptive effects with reduced systemic side effects compared to other ñ agonists.
Fadolmidine acts as a selective ñ adrenergic receptor agonist, a receptor class associated with modulation of nociceptive signalling. A 2004 review described preclinical evidence of spinal antinociceptive effects in laboratory models and suggested a reduced propensity for sedation compared with systemic ñ agonists.
The compound was developed under the code MPV-2426. As of 2025, it has no approved medical indication and has not advanced to late-stage clinical development.
Fadolmidine is an imidazole-derived compound structurally related to other ñ agonists such as medetomidine and dexmedetomidine.